Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial

BACKGROUND: Individuals who are immunocompromised (IC) are at high risk for severe coronavirus disease 2019 (COVID-19). METHODS: Post hoc analyses of a double-blind trial conducted prior to Omicron (June 2020–April 2021), in hospitalized patients with COVID-19 assessed viral load, clinical outcomes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Somersan-Karakaya, Selin, Mylonakis, Eleftherios, Mou, Jenni, Oviedo-Orta, Ernesto, O’Brien, Meagan P, Mas Casullo, Veronica, Mahmood, Adnan, Hooper, Andrea T, Hussein, Mohamed, Ali, Shazia, Marty, Francisco M, Forleo-Neto, Eduardo, Bhore, Rafia, Hamilton, Jennifer D, Herman, Gary A, Hirshberg, Boaz, Weinreich, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205469/
https://www.ncbi.nlm.nih.gov/pubmed/37229174
http://dx.doi.org/10.1093/ofid/ofad211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205469/
https://www.ncbi.nlm.nih.gov/pubmed/37229174
http://dx.doi.org/10.1093/ofid/ofad211

Ejemplares similares